NCT00765947

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 256 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure \[msSBP\] ≥ 140 mmHg and \< 180 mmHg and/or mean sitting Diastolic Blood Pressure \[msDBP\] ≥ 90 and \<110 mmHg).

Conditions

• Essential Hypertension ( Mild to Moderate)

Interventions

Type	Name	Description
DRUG	Aliskiren	Aliskiren 150 or 300 mg
DRUG	Hydrochlorothiazide	Hydrochlorothiazide 12.5 or 25 mg
DRUG	Amlodipine	Amlodipine 5 or 10 mg

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2008-10-03
• Last updated: 2020-08-06
• Results posted: 2011-01-11

Locations

4 sites across 4 countries: France, Hungary, Romania, Slovakia